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Abstract: Melanoma is the deadliest form of skin cancer due to its ability to colonize distant sites
and initiate metastasis. Although these processes largely depend on the lipid-based cell membrane
scaffold, our understanding of the melanoma lipid phenotype lags behind most other aspects of
this tumor cell. Here, we examined a panel of normal human epidermal and nevus melanocytes
and primary and metastatic melanoma cell lines to determine whether distinctive cell-intrinsic
lipidomes can discern non-neoplastic from neoplastic melanocytes and define their metastatic po-
tential. Lipidome profiles were obtained by UHPLC-ESI mass-spectrometry, and differences in the
signatures were analyzed by multivariate statistical analyses. Significant and highly specific changes
in more than 30 lipid species were annotated in the initiation of melanoma, whereas less numerous
changes were associated with melanoma progression and the non-malignant transformation of nevus
melanocytes. Notably, the “malignancy lipid signature” features marked drops in pivotal membrane
lipids, like sphingomyelins, and aberrant elevation of ether-type lipids and phosphatidylglycerol
and phosphatidylinositol variants, suggesting a previously undefined remodeling of sphingolipid
and glycerophospholipid metabolism. Besides broadening the molecular definition of this neoplasm,
the different lipid profiles identified may help improve the clinical diagnosis/prognosis and facilitate
therapeutic interventions for cutaneous melanoma.
Keywords: lipid biomarker; lipid phenotype; human; melanoma; melanocyte; nevus melanocyte;
sphingomyelin; plasmalogen; ether lipid; metastasis
1. Introduction
Melanoma is regarded as the deadliest form of skin cancer, arising after the malignant
transformation of neural crest-derived melanocytes in the epidermis of the skin [1]. The
transformation of these cells is due to a plethora of molecular alterations (reviewed in [2]),
including activating mutations in the proto-oncogene kinase BRAF. In conjunction, these
not only account for the aggressiveness of melanoma and its ability to metastasize to other
organs but also the strong intratumoral heterogeneity and lack of specific biomarkers with
high diagnostic accuracy. Thus, discovering new biomarkers and elucidating the molecular
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events underlying melanoma initiation and progression will be necessary to develop more
selective and powerful therapies for melanoma patients.
Metabolic changes are observed in most cancer cells, including accelerated nutrient
import and metabolic rewiring to enhanced aerobic glycolysis [3–10]. Alterations in lipid
metabolism and the development of a lipogenic phenotype have also emerged as early
biochemical hallmarks of cancer cells [11–18]. In this regard, studies assessing the metabolic
behavior of melanoma have demonstrated that such phenotypic plasticity confers adap-
tive advantages favoring proliferation and survival [4,19,20]. For instance, while the de
novo biosynthesis of fatty acids (FA) is mild in normal adult tissues, the tumorigenesis-
associated increase in lipid production enables cells to create a strategically structured
new biomass [12,13], helping them better handle changing environmental conditions [3].
Growth and lipid metabolism are reciprocally linked through transcriptional programs op-
erated by sterol regulatory element-binding protein-1 (SREBP-1) [21,22]. In a recent study
of melanoma cells, not only was it confirmed that de novo lipogenesis relies essentially on
the proteolytic activation of SREBP-1, but also, it was demonstrated that lipogenesis is a key
mediator of the oncogenic tumor effects of BRAF implicated in resistance to therapy [23].
They demonstrated that while de novo lipogenesis is inhibited by BRAFv600E-targeted
therapy in BRAF-mutant cells sensitive to therapy, cells resistant to therapy invariably
rescue SREBP-1 processing and lipogenesis [23]. Since de novo lipogenesis is mainly
responsible for the formation of saturated FA (i.e., C16:0), which are rapidly incorpo-
rated into neutral lipids and phospholipids, therapy-resistant cells exhibit an increase in
membrane saturation [23]. Other features of lipid biochemistry also seem to be critical
to the aggressiveness of melanoma cells, such as the enhanced provision of endogenous
FA and protumorigenic signals through lipolytic monoacylglycerol lipase [14,15] and the
acquisition of lipids from the extracellular space by metastasis-initiating cells through the
FA receptor CD36 [24] or those from stromal adipocytes through FATP lipid transporter
proteins [25]. Thus, differential lipid signatures might yield molecular biomarkers for the
diagnosis and/or prognosis of melanoma, although data on the lipidome of melanoma
cells are still somewhat limited.
Lipids play essential roles in a plethora of cellular and systemic processes, including
cell compartmentalization, signaling and migration; fuel management; and protein traffick-
ing and sorting [17,26,27]. To accomplish this, cells produce lipids with a vast structural
complexity and diversity. A paradigmatic case is that of the membrane glycerophospho-
lipids, as interconnected biochemical pathways, together with deacylation/reacylation
processes, generate hundreds of molecular variants in terms of polar head groups (that
determine the lipid class) and hydrophobic acyl chains (that determine the individual
molecular species within a class). Schemes of core glycerophospholipid and sphingolipid
biosynthetic pathways can be seen in Figure 1. This metabolic strategy provides a competi-
tive advantage in nature, yielding a dynamic scaffold for cell membranes that allow cells to
respond to changes in homeostasis and environmental cues. The response, however, may
be short-lived. When it comes to the discovery of lipid biomarkers in tumor cells, a funda-
mental question is whether the expression of individual lipids that are formed through the
pathways downstream of oncogenic signals (lipogenesis and others) can be measured and
if they differ consistently from those of cells undergoing normal physiological turnover.




Figure 1. Core glycerophospholipid (A) and sphingolipid (B) biosynthetic pathways. 
Mass spectrometry (MS)-based lipidomics offer a unique opportunity to study and 
screen hundreds of lipid species simultaneously, making it well-suited to lipid biomarkers 
discovery [28]. However, the structural complexity of lipids mentioned above and the nu-
merous isomeric and isobaric species harboring the same backbone and acyl chains pose 
a major challenge to their identification. To the best of our knowledge, there have been 
few studies that have attempted to characterize the lipid profiles in melanocytes. Nano-
electrospray ionization (ESI) chip-based direct infusion MS (DIMS), an analytical method 
Figure 1. Core glycerophospholipid (A) and sphingolipid (B) biosynthetic pathways. Enzymes (A): ADHAPS: alkylD-
HAP synthase; AGPAT: acyl:glycerol-3-phosphate acyltransferase; CDS: CDPDG synthase; CHPT: CDP:phosphocholine
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phosphotransferase; CK: choline kinase; CLS: cardiolipin synthase; DGAT: DG acyltransferase; DGK: DG kinase.
DHAPAT: DHAP acyltransferase; EK: ethanolamine kinase; EPT1: ethanolamine phosphotransferase; FAR1/2: fatty
acyl-CoA reductase1/2; GPDH: glycerol-3-phosphate dehydrogenase; GPAT: glycerol-3-phosphate acyltransferase;
LCLAT: acyl-CoA:lysocardiolipin acyltransferase; LPCAT: acyl-CoA:lysophosphatidylcholine acyltransferase; LPGAT:
acyl.CoA:lysophosphatidylglycerol acyltransferase; PAP: phosphatidic acid phosphatase (lipin). PCYT1: phosphocholine-
transferase; PCYT2: phosphoethanolaminetransferase; PEMT: SAM-phosphatidylethanolamine methyltransferase; PGPS:
phosphatidylglycerophosphate synthase; PGPP: phosphatidylglycerophosphate phosphatase; PIS: phosphatidylinositol
synthase; PISD: phosphatidylserine decarboxylase; PLA1/2: phospholipase A1/2; PLC: phospholipase C; PSS1/2: phos-
phatidylserine synthase 1/2; TGL: triacylglycerol lipase. Enzymes (B): ACER: alkaline ceramidase; CERK: ceramide
kinase; CERS: Ceramide synthase; DES: sphingolipid 4-desaturase; GCST: galactosylceramide sulfotransferase; KDSR:
3-ketodihydrosphingosine reductase; PAP: phosphatidic acid phosphatase; SCPT: sphingosine cholinephosphotransferase;
SmaseD: sphingomyelinase D; SMS: sphingomyelin synthase; SPT: serine:palmitoyltransferase; UGCG: ceramide glucosyl-
transferase; UGT8: ceramide galactosyltransferase.
Mass spectrometry (MS)-based lipidomics offer a unique opportunity to study and
screen hundreds of lipid species simultaneously, making it well-suited to lipid biomarkers
discovery [28]. However, the structural complexity of lipids mentioned above and the
numerous isomeric and isobaric species harboring the same backbone and acyl chains pose
a major challenge to their identification. To the best of our knowledge, there have been
few studies that have attempted to characterize the lipid profiles in melanocytes. Nano-
electrospray ionization (ESI) chip-based direct infusion MS (DIMS), an analytical method
without prior chromatographic separation of the lipid classes, was used to identify 65 lipids
in the 500–900 m/z range expressed in HEMn-LP melanocytes and in two melanoma
cell lines with low (A375) and high (A2058) metastatic potential [29]. When combined
with a metabolomics approach, a partial least squares (PLS) projection to latent structure
regression (PLSR) prediction model was developed to define a panel of six lipid species
and 10 metabolites that differentiated melanocytes from melanoma cells with different
metastatic potential. Prior to this, only the total lipid content and composition of certain
melanoma cell lines had been examined [30]. On the other hand, we addressed the in situ
classification of architectural features of benign intradermal melanocytic nevus lesions
using imaging MS (IMS), developing a lipid expression-based algorithm that discriminates
epidermis, dermis and melanocytes [31]. Consistent with the metabolic heterogeneity
of melanoma cells within a single lesion [2], our IMS study also revealed distinct lipid
phenotypes in melanocyte subpopulations within a single nevus, hinting that limited
sample size (cell lines or nevus samples) may provide too narrow a window to obtain
valuable biological information. Moreover, there are no lipidomic analyses of isolated
benign human nevi melanocytes to date.
Nowadays, tandem MS preceded by ultrahigh performance liquid chromatography
(UHPLC) separation of lipid classes is the method of choice in untargeted lipidomics [32].
This approach greatly enhances the accuracy and the sensitivity to identify low abundance
lipids. Given the limitations mentioned above, here, we attempted to achieve extended
coverage of the human melanocyte lipidome and test the hypothesis that a particular lipid
fingerprint could discern benign and malignant melanocytes as well as melanoma cells
with different metastatic potential. As such, we conducted untargeted UHPLC-MSE–based
lipidomics on a panel of human epidermal melanocytes (HeM) and nevus melanocytes
(NM), as well as on primary (PM) and metastatic (MM) melanoma cells grown in vitro
(n = 4–10 per group). This study demonstrated that melanocytes exhibit a lipid phenotype
characteristic of their biological status. Specifically, we identified a set of lipid metabolites
that segregate epidermal and nevus melanocytes from either of the two melanoma groups,
in which sphingomyelins and ether lipids play a fundamental role.
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2. Results
2.1. Global Lipidomic Analysis of Human Melanocytic Cells
Lipidomic profiling of non-neoplastic and neoplastic melanocytic cells using our
UHPLC-MSE analytical platform enabled 209 lipid species to be identified and quantified
in all the tested samples. The full list of lipid species and their corresponding peak markers
and intensities can be seen in Table S1 and are summarized in Table 1. These metabolites be-
long to 16 classes from five lipid categories: sphingolipids—sphingomyelin (SM), ceramide
(Cer) and hexosylceramide (HexCer), sterol lipids—cholesteryl ester (CE), glycerolipids—
triglycerides (TG) and diglycerides (DG), glycerophospholipids—phosphatidylcoline (PC),
lysoPC (LPC), phosphatidylethanolamine (PE), lysoPE (LPE), phosphatidylserine (PS),
phosphatidylglycerol (PG), phosphatidylinositol (PI) and ether phospholipids PC(O/P)
and PE(O/P) and free fatty acids (FA). For SM, HexCer, CE, TG, DG, PC, LPC and PC(O/P)
the most intense ion was detected in positive polarity either as the protonated molecular
ion or as the sodium or [M+NH4]+ adducts, whereas PE, LPE, PE(O/P), PS, PG, PI and
FA were observed in negative ion mode as [M-H]-. In addition, our platform identified
different Cer species in the two ionization modes, whereas, due to the low ionization
capacity of sterols in ESI, only the neutral cholesteryl esters were recorded. In terms of
the structural variability, storage TG exhibited by far the highest diversity, with 51 species
identified, followed by FA and PC with 24 and 22 molecular variants, and PE plasmalogen
and SM with 18 and 17 species, respectively.
Table 1. Lipid metabolites identified by lipidomics in non-neoplastic and neoplastic melanocytes. A total of 209 lipid species
from 16 classes were identified in each of the samples analyzed in the positive and negative ion modes of UHPLC-MSE.






Sphingomyelin SM 17 [SM+H]+ SM d18:1/16:0
Hexosylceramide HexCer 3 [HexCer+Na]+ HexCer d18:1/24:1
Ceramide Cer 2 [Cer+Na]+ Cer d18:1/24:1
Ceramide Cer 6 [Cer-H]− Cer d18:1/16:0
Sterol lipids Cholesteryl ester CE 6 [CE+NH4]+ CE 15:0
Glycerolipids Triglyceride TG 51 [TG+NH4]+ TG 52:3
Diglyceride DG 7 [DG+Na]+ DG 36:0
Glycerophospholipids
Phosphatidylcholine PC 22 [PC+H]+ PC 16:0/18:1
Lysophosphatidylcholine LPC 1 [LPC+H]+ LPC 18:1
Ether-PC PC(O/P) 1 5 [PC(O)+H]+ PC O-16:0/18:1
Phosphatidylethanolamine PE 12 [PE-H]− PE 18:0/18:1
Lysophosphatidylethanolamine LPE 4 [LPE-H]− LPE 20:4
Ether-PE PE(O/P) 1 18 [PE(P)-H]− PE P-16:0/18:1
Phosphatidylserine PS 8 [PS-H]− PS 18:0/18:1
Phosphatidylglycerol PG 8 [PG-H]− PG 16:0/18:0
Phosphatidylinositol PI 15 [PI-H]− PI 18:0/20:4
Fatty acyls Fatty acid FA 24 [FA-H]− FA 18:0
1 In the shorthand notation for ether species, O− and P− represent the ether and vinyl ether bonds of alkyls at the sn-1 position of the
glycerol backbone, respectively.
2.2. Different Lipid Signatures Feature Nonneoplastic and Neoplastic Melanocytic Cells
To investigate the similarity of the lipid profiles in the samples, we applied multivari-
ate statistical analysis to the data. The values for the quality parameters R2 (goodness of fit)
and Q2 (ability of prediction) of the principal component analysis (PCA) plots (Figure 2A,B)
indicate that the distinctive lipid expression was sufficient to group the samples according
to their biology. All benign melanocytes were grouped in the same cluster and melanomas,
in a different one. Nonetheless, the algorithm did not clearly discriminate melanoma
cells according to their metastatic potential and some overlap between HeM and NM was
evident in the positive-ion mode. All binary comparisons in the partial least square dis-
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criminant analysis (PLS-DA) produced a net group separation (NM vs. HeM, PM vs. HeM,
MM vs. HeM, PM vs. NM, MM vs. NM, MM vs. PM), indicating that each cell type has a
characteristic lipid profile in both ESI+ and ESI-. The results of this supervised analysis
mimic what might be a canonical progressive transformation of epidermal melanocytes
(Figure 2C–G). As shown, the differences between lipid patterns were striking in some
cases, such as between PM and NM or MM and NM (Figure 2D,E), while they were subtle
in others, such as between MM and PM (Figure 2F). PLS-DA further confirmed that the
lipidome of melanocytes, taken as a single group (HeM+NM), differed markedly from the
“malignant lipidome” harbored by PM-and-MM (Figure 2G).




Figure 2. Multivariate statistical analysis of melanocytic cell lipidomes clearly discriminates benign from malignant cells. 
The principal component analysis (PCA) score plots of lipidomes obtained in the positive (A) and the negative (B) ion 
modes of UHPLC-MSE are illustrated according to the independent cell samples (n = 4–10). Green, blue, yellow and red 
symbols indicate human epidermal melanocytes (HeM), nevus melanocytes (NM), primary melanoma (PM) and meta-
static melanoma (MM), respectively. Binary comparisons constructed through partial least square-discriminant analysis 
(PLS-DA): (C) NM vs HeM, (D) PM vs NM, (E) MM vs NM, (F) MM vs PM, (G) melanoma (PM+MM, orange) vs melanocyte 
(HeM+NM, blue). 
To validate the PLS-DA prediction models, we conducted permutation tests, record-
ing the cumulative values of R2 and Q2 for 999 random rearrangements of the Y variables 
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of UHPLC-MSE are illustrated according to the independent cell samples (n = 4–10). Green, blue, yellow and red symbols
indicate human epidermal melanocytes (HeM), nevus melanocytes (NM), primary melanoma (PM) and metastatic melanoma
(MM), respectively. Binary comparisons constructed through partial least square-discriminant analysis (PLS-DA): (C) NM vs.
HeM, (D) PM vs. NM, (E) MM vs. NM, (F) MM vs. PM, (G) melanoma (PM+MM, orange) vs. melanocyte (HeM+NM, blue).
To validate the PLS-DA prediction models, we conducted permutation tests, recording
the cumulative values of R2 and Q2 for 999 random rearrangements of the Y variables
and thereafter, reconstructing the models (Table 2). The negative intersection of the Q2Y
line of tendency obtained for all the models demonstrated that the PLS-DA data are well
adjusted and the clustering was not by chance. An additional test, using p-values obtained
from CV-ANOVA (Analysis of Variance testing of Cross-Validated predictive residuals)
also confirmed the validity of the models, except for the MM vs. PM comparison in
ESI+. Hence, the R2, Q2, permutation Q2 and p-values (Table 2) indicated that the models
established reliably discriminate the cell groups based on their lipid fingerprint, except for
the lipidomes of MM and PM in ESI+ that may not be sufficiently distinct to be clustered
separately by this approach.
Table 2. Validation of the PLS-DA models.
Model IonizationMode
Principal Components,
Minimum 1 R2 Q2 Q2 Intercept p-Value
2
NM vs. HeM
+ 2 0.831 0.595 −0.218 1.07 × 10−2
− 1 0.741 0.509 −0.147 4.10 × 10−2
PM vs. HeM
+ 3 0.966 0.908 −0.399 6.14 × 10−4
− 2 0.967 0.929 −0.346 4.54 × 10−5
MM vs. HeM
+ 2 0.949 0.907 −0.246 1.28 × 10−4
− 2 0.971 0.930 −0.280 3.15 × 10−5
PM vs. NM
+ 3 0.976 0.919 −0.444 1.21 × 10−4
− 3 0.968 0.870 −0.442 1.52 × 10−4
MM vs. NM
+ 2 0.972 0.945 −0.345 7.42 × 10−8
− 1 0.953 0.938 −0.262 8.45 × 10−10
MM vs. PM
+ 1 0.516 0.201 −0.076 1.48 × 10−1
− 4 0.965 0.825 −0.495 2.94 × 10−3
PM and MM vs.
HeM and NM
+ 3 0.944 0.879 −0.382 2.09 × 10−10
− 4 0.967 0.891 −0.544 9.86 × 10−9
1 Minimum number of principal components required to explain the maximum variance. 2 The validity of the model according to that
minimum number of principal components. HeM, human epidermal melanocytes; NM, nevus melanocytes; PM, primary melanoma; MM,
metastatic melanoma.
2.3. Changes in the Relative Abundance of Particular Lipid Species Reflect the Melanocyte Biology
To extract putative lipid biomarkers of melanocytes in different states, we performed
a multivariate orthogonal partial least square-discriminant analysis (OPLS-DA) of the lipid
fingerprints, employing the following threshold parameters: fold-change > 1.3 or < 0.7 (ion
peak intensity ratio), coefficient of variation < 30%, ANOVA p < 0.05, variable importance in
the projection (VIP) > 1.0. This approach enabled the top discriminant lipids to be selected
(Table 3). An example of the selection of discriminant lipids between PM and NM is shown
in Figure 3A,B.
A set of 53 lipid metabolites showed the strongest discriminatory power across groups
(about 25 % of the total number of lipid species identified), including PC(O), PE(P), PG,
PI, PE, PC, SM, TG and FA (100, 39, 62, 60, 17, 5, 47, 20 and 25 % of the molecules in their
respective classes). The identities, the detection parameters and the typical changes of
these species are reported in Table 3. Intergroup differences were confirmed by several
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univariate statistical analyses. In particular, the p-values from the ANOVA with post hoc
testing (Levene and Tukey or Games–Howell tests) are shown (Table 3, see asterisks).
Volcano plots and heatmap clustering were performed applying a fold change >2
and a p-value ≤ 0.05 by Student’s t-test using Benjamini–Hochberg as a multiple testing
correction (Figure S1). Having less stringent discriminant statistical power than the OPLS-
DA thresholds we assigned, univariate analyses expanded the list of potential biomarkers.
Typically, new molecular species were added within the same lipid classes defined by
OPLS-DA (Table 3).




Figure 3. Representative selection of discriminant lipids by OPLS-DA. The lipidomes of primary melanoma (PM) and 
nevus melanocytes (NM) obtained in ESI+ (A) and ESI- (B) were evaluated by OPLS-DA for candidate biomarker selection. 
In the score plots of the two main components (1), discriminant lipids were visualized as S-plots (2), VIP plots (3), and 
loading plots calculated by the jack-knife algorithm. Red and blue denote the variables that are more and less abundant 
in PM than in NM, respectively. 
 
Figure 3. Representative selection of discriminant lipids by OPLS-DA. The lipidomes of primary melanoma (PM) and nevus
melanocytes (NM) obtained in ESI+ (A) and ESI- (B) were evaluated by OPLS-DA for candidate biomarker selection. In the
score plots of the two main components (1), discri inant lipids were visualized as S-plots (2), VIP plot (3), and loading
plots calculated by the jack-knife algorithm. Red and blue denote the variables that are more and less abundant in PM than
in NM, respectively.
Int. J. Mol. Sci. 2021, 22, 12061 9 of 20
Table 3. Discriminant lipid metabolites of melanocyte biology extracted by OPLS-DA.
Lipid Adduct Characterized m/z RT NM vs. HeM PM vs. HeM MM vs. HeM PM vs. NM MM vs. NM MM vs. PM PM+MM vs.HeM+NM
PC O-30:0 [PC(O-30:0)+H]+ 692.5601 4.39 down *** up *** up ** up *** up ***
PC O-32:1 [PC(O-32:1)+H]+ 718.5743 4.48 down ** up ** up *** up *** up ***
PC O-16:0/16:0 [PC(O-16:0/16:0)+H]+ 720.5921 5.02 down *** up *** up *** up *** up ***
PC O-16:0/18:1 [PC(O-16:0/18:1)+H]+ 746.6087 5.08 down *** up *** up *** up *** up ***
PC O-36:2 [PC(O-36:2)+H]+ 772.6240 5.13 down *** up *** up * up *** up **
PE P-16:0/16:1 [PE(P-16:0/16:1)-H]− 672.4963 4.59 up
PE P-16:0/20:5 [PE(P-16:0/20:5)-H]− 720.4969 4.20 up *** up *** up *** up *** up ***
PE P-16:0/22:6 [PE(P-16:0/22:6)-H]− 746.5122 4.42 up *** up ** up *** up *** up ***
PE P-38:4 [PE(P-38:4)-H]− 750.5421 5.17 down * down down *** down *** down ***
PE P-38:3 [PE(P-38:3)-H]− 752.5569 5.45 down down down *** down ** down ***
PE P-18:0/22:6 [PE(P-18:0/22:6)-H]− 774.5456 5.03 up *** up *** up ***
PE P-18:0/22:4 [PE(P-18:0/22:4)-H]− 778.5733 5.56 down ** down * down **
PG 32:0 [PG(32:0)-H]− 721.4996 4.21 up *** up *** up *** up *** up ***
PG 18:0/16:1 [PG(18:0/16:1)-H]− 747.5139 4.47 up *** up ** up *** up *** up ***
PG 36:1 [PG(36:1)-H]− 775.5451 5.04 up *** up *** up ***
PG 18:1/18:2 [PG(18:1/18:2)-H]− 771.5170 3.13 down *** down **
PG 18:1/20:2 [PG(18:1/20:2)-H]− 799.5449 3.62 down *** down *** down *** up *** down ***
PI 32:1 [PI(32:1)-H]− 807.5026 3.10 up *
PI 16:1/18:0 [PI(16:1/18:0)-H]− 835.5326 3.67 up *
PI 16:0/20:4 [PI(16:0/20:4)-H]− 857.5176 3.14 up ***
PI 18:0/18:2 [PI(18:0/18:2)-H]− 861.5506 3.75 up ***
PI 16:0/20:1 [PI(16:0/20:1)-H]− 863.5633 4.26 up *
PI 18:1/20:4 [PI(18:1/20:4)-H]− 883.5350 3.24 up ***
PI 18:0/20:2 [PI(18:0/20:2)-H]− 889.5792 4.31 up *** up **
PI 40:6 [PI(40:6)-H]− 909.5487 3.59 up *** up *** up *** up *** up ***
PI 40:5 [PI(40:5)-H]− 911.5645 3.76 up ** up *** up *** up ***
PE 18:0/20:3 [PE(18:0/20:3)-H]− 768.5539 5.25 down down * down *
PE 18:0/22:4 [PE(18:0/22:4)-H]− 794.5681 5.25 down *** down *** down *** down * down ***
PC 38:3 [PC(38:3)+H]+ 812.6182 4.92 down *** down *** down *** down ***
SM d18:1/14:0 [SM(d18:1/14:0)+H]+ 677.5562 3.38 down ** down ***
SM d18:1/16:0 [SM(d18:1/16:0)+H]+ 703.5790 3.93 down *** down *** down *** down *** down ***
SM d18:0/16:0 [SM(d18:0/16:0)+H]+ 705.5837 3.97 down *** down *** down *** down *** down ***
SM d18:1/22:1 [SM(d18:1/22:1)+H]+ 785.6613 5.23 down * down *** down ***
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Table 3. Cont.
Lipid Adduct Characterized m/z RT NM vs. HeM PM vs. HeM MM vs. HeM PM vs. NM MM vs. NM MM vs. PM PM+MM vs.HeM+NM
SM d18:1/22:0 [SM(d18:1/22:0)+H]+ 787.6701 5.76 down *** down down *** down ** down ***
SM d18:1/24:1 [SM(d18:1/24:1)+H]+ 813.6875 5.74 down *** down *** down *** down ***
SM d18:1/24:0 [SM(d18:1/24:0)+H]+ 815.7000 6.31 down down down *** down ** down **
SM d18:1/26:1 [SM(d18:1/26:1)+H]+ 841.7153 6.27 up down *** down **
TG 50:4 [TG(50:4)+NH4]+ 844.7390 7.99 down down down * down ***
TG 52:6 [TG(52:6)+NH4]+ 868.7380 7.76 down *** down ***
TG 52:5 [TG(52:5)+NH4]+ 870.7568 7.99 down *** down ***
TG 52:4 [TG(52:4)+NH4]+ 872.7720 8.22 down *** down *** down ***
TG 54:5 [TG(54:5)+NH4]+ 898.7851 8.24 down *** down *** down *** down ***
TG 54:4 [TG(54:4)+NH4]+ 900.8043 8.47 down *** down *** down ***
TG 56:5 [TG(56:5)+NH4]+ 926.8162 8.55 down *** down *** down ***
TG 56:4 [TG(56:4)+NH4]+ 928.8324 8.73 down *** down ***
TG 58:5 [TG(58:5)+NH4]+ 954.8464 8.77 down ** down *** down ** down ***
TG 58:4 [TG(58:4)+NH4]+ 956.8638 8.92 down *** down *** down ** down ***
FA 20:4 [FA(20:4)-H]− 303.2335 1.24 down down down *
FA 20:3 [FA(20:3)-H]− 305.2482 1.52 down *** down ***
FA 20:2 [FA(20:2)-H]− 307.2624 1.82 down down *** down ***
FA 22:4 [FA(22:4)-H]− 331.2637 1.62 down *** down *** down *** down *** down ***
FA 22:3 [FA(22:3)-H]− 333.2795 2.01 down *** down *** down *** down *** down ***
FA 22:2 [FA(22:2)-H]− 335.2944 2.43 down *** down *** down *** down ** down ***
The asterisks indicate significant intergroup differences following one-way ANOVA and post-hoc testing with Tukey (p ≥ 0.05) or Games–Howell’s (p ≤ 0.05) after assessing the equivalence of the variances
by Levene’s test: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. RT, retention time; m/z, mass-to-charge ratio; HeM, human epidermal melanocytes; NM, nevus melanocytes; PM, primary melanoma; MM, metastatic
melanoma; PC, phosphatidylcholine; PC-O, ether PC; PE, phosphatidylethanolamine; PE-P, vinyl ether PE; PG, phosphatidylglycerol; PI, phosphatidylinositol; SM, sphingomyelin; TG, triglyceride; FA, fatty acid.
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From a biological perspective, it is worth noting that our findings revealed that
1—sphingomyelins and glycerophospholipids contributed most significantly to the pheno-
typic diversity of melanocytes; 2—the changes in glycerophospholipids were highly selec-
tive, showing functional group, FA and FA-linkage type specificity; 3—lipid fingerprints
strongly differentiated between neoplastic and non-neoplastic melanocytes; 4—there were
significant differences, although less numerous, in lipid species between melanoma cells
with different metastatic potential and between epidermal and benign nevus melanocytes.
The dominating characteristic of melanoma cells compared to normal melanocytes
was the elevation of ether-type PC (100% of the total number of molecules within this class)
and the dramatic decrease in SM, involving 8 of the 17 molecules identified that represented
around 80% of the total SM intensity. An incorrect pattern of PE plasmalogens and PG
was also found in melanoma, characterized by the presence of some strongly expressed
species while others were dampened intensely, along with a decrease in some TG and FA
species. The intensity of lipid species eliciting opposing trends in the experimental groups
is exemplified by the ethyl ethers PC O-16:0/16:0 and PC O-16:0/18:1, which are expressed
more strongly in malignant cells (Figure S2A), and by SM d18:1/16:0 and PE P-18:0/22:4,
that were particularly abundant in melanocytes (Figure S2B). Figure S2 also provides clear
examples of the heterogeneity in lipid expression across the cell lines analyzed, which were
used to model a condition, as also seen for colon cancer cell lines [33].
An additional finding that may have signaling consequences is the increased relative
abundance of PI species in metastatic melanoma cells in respect to normal melanocytes
(most markedly versus nevi melanocytes).
It is important to underline that similar and specific differences were observed in
PM and MM lipidomes to those observed in epidermal and nevi melanocytes (see Venn
diagrams in Figure 4B). For instance, similar changes in nineteen lipids, a decrease in 16
and an increase in three molecular species differentiated primary melanoma from both
epidermal and nevus melanocytes, suggesting that this common phenotypic remodeling
may be associated with tumor initiation and the maintenance of primary melanoma. The
32 candidate biomarkers of malignancy extracted from the PM+MM vs. HeM+NM analysis
were examined in more detail (Figure 4B). Discriminant lipids belong to nine classes: five
choline ether and five ethanolamine ether lipids, 1 PC, 1 PE, 2 PI, 3 PG, 5 SM, 3 FA and
7 TG (only four are plotted). Interestingly, there was a selective and striking shift in species
from a diacyl-type PC and PE to PC ether and PE plasmalogens, and in particular to
low unsaturated PC ether species and to plasmalogens presenting 20:5 (eicosapentaenoic
acid, EPA) or 22:6 (docosahexaenoic acid, DHA) at the sn-2 position. In addition, low
levels of most SM species and of 20C and 22C FA were part of the common composite of
malignant melanocytes, in conjunction with aberrant PG expression, a lipid class unique to
mitochondrial membranes [34].
As mentioned earlier, a literature search failed to retrieve any lipidomic data from
melanocytes isolated from clinically diagnosed benign nevus. By contrast, here we defined
a detailed lipidome for the NM and HeM phenotypes (Table S1) and compared their profiles
(Figures 2C and 4, Table 3). Apart from a switch in a pair of SM species, an interesting
finding was the decline of all PC ethers to levels below 25% of those recorded in HeM.
The melanocyte lipid landscape was further analyzed by assessing whether the varia-
tions in species abundance affect the relative expression of the total lipid classes. To study
this, we assessed the sums of the intensities of all the lipid species within each class (for
the source data, see Table S1). Statistically significant differences were observed among
some classes by ANOVA and post-hoc testing (Levene and Tukey or Games–Howell)
(Figure S3A–C) that revealed a general trend towards expanded signaling lipids PI, PG,
Cer and DG in metastatic melanoma as opposed with primary melanoma. Once again,
choline ether phospholipids were expanded while SM plummeted in neoplastic cells rel-
ative to non-neoplastic melanocytes. Therefore, abnormal signaling pathways may be
envisaged in melanoma cells with high metastatic potential, in addition to remodeling of
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ether glycerophospholipids and sphingolipid metabolism in melanoma cells irrespective of
their metastatic potential.
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3. Discussion
Different models have been proposed to explain melanoma progression and one of
the most popular, the Clark model, considers the melanoma development to be a linear
and stepwise transformation: benign nevi, dysplastic nevi, primary melanoma in the
radial growth phase, primary melanoma in the vertical growth phase and metastatic
melanoma. However, many melanoma tumors may not follow such an orderly progression.
Nevertheless, over the past two decades, the biochemical changes that accompany these
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transitions have begun to be defined, although the molecular mechanisms that distinguish
the pathological and benign transformations of melanocytes have yet to be fully explored.
As such, it remains unclear whether these differences can be targeted therapeutically.
Here we studied HeM, NM, PM and MM cells through untargeted UHPLC-MSE-
based lipidomics, defining different lipid signatures related to the benign and malignant
transformation of melanocytes. We identified significant changes to 53 lipid species that
tell us more about how melanoma grows and spreads and how nevus melanocytes do not
share the perturbations in the lipid metabolism of melanoma cells. In fact, the most promi-
nent differences across groups were observed between nevus melanocytes and primary
and metastatic melanoma cells. We further identified distinctive traits between NM and
HeM involving ether PC species, between MM and PM involving six lipids and between
malignant melanoma cells and normal melanocytes that revealed 32 biomarker candidates.
A first remarkable observation is the selective accumulation of ether PC lipids in
primary and metastatic melanoma, whereas, in strong contrast, nevus melanocytes were
depleted in PC ethers relative to epidermal melanocytes. Thus, ether PC levels can distin-
guish a benign from a malignant transformed cell, discriminating the melanocyte status.
Ether glycerophospholipids represent an important group of membrane phospholipids
in which the hydrocarbon chain is linked by an ether (O) or vinyl ether (P) bond at the
sn-1 position of the glycerol backbone. In mammals, ether phospholipids are initially
synthesized in peroxisomes (driven by the FAR1 and FAR2 enzymes that catalyze the
required reduction of a fatty acid to a fatty alcohol) and processed in the endoplasmic
reticulum (ER) [35,36]. Ether phospholipids are known to be involved in signaling, the
export of GPI-anchored proteins from the ER and the resistance to insults like oxidative
stress [35,37–40] and ferroptosis [41]. The increased generation of reactive oxygen species
(ROS) due to an enhanced metabolic activity is a common stressor to which cancer cells
must adapt and buffer. This increased generation of ROS can play a dual role in the cancer
phenotype: a tumorigenic role promoting growth and genomic instability or be toxic and
induce cell death (reviewed in [10]). However, in non-neoplastic cells, ROS promotes
senescence and apoptosis. Thus, it is conceivable that peroxisome-driven enrichment
in ether PC would confer a survival advantage during tumorigenesis and metastasis,
providing melanoma cells strong protection due to their antioxidant-scavenging capacity
upregulation. By contrast, the drop of ether lipids in normal nevus melanocytes would
render cells to a state that makes them vulnerable to senescence and apoptosis. Untangling
the molecular determinants of ether PC depletion in nevus melanocytes, a finding first
reported here, will likely offer additional insight to devise strategies that target redox
homeostasis in melanoma.
Notably, PE plasmalogens did not follow the ether PC trends. Instead, exchanges of
one PE plasmalogen species for another were observed among different groups, suggesting
that a second non-peroxisomal level of regulation may exist. Interestingly, two DHA-
containing plasmalogens, PE P-16:0/22:6 and PE P-18:0/22:6, were identified as potential
biomarkers of metastasis. In plasmalogens, the vinyl ether bond is formed at the ER
from the corresponding ether PE precursor in a recently discovered, TMEM189-catalyzed
reaction [42]. It is tempting to speculate that TMEM189 expression or function may be
driven by specific signals with implications in metastasis. This is consistent with findings of
a recent expression profile analysis of TMEM189 in the cancer databases that revealed that
cancer patients expressing higher levels of TMEM189 have a significantly shorter overall
survival compared to patients bearing tumors expressing lower levels of TMEM189 [41].
A second remarkable feature is that SM, both as a class and in terms of the major
SM species, are underrepresented in neoplastic cells, with similar levels in primary and
metastatic melanoma. Because SMs are essential components of cell membranes, this may
be functionally relevant. Besides influencing membrane fluidity, SMs are known to regulate
critical aspects of cell division, proliferation and chemotaxis, events that could contribute
to cancer development (we refer the reader to two recent excellent reviews [43,44]). SM
forms membrane microdomain platforms—along with cholesterol and plasmalogens—to
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transduce transmembrane signals with wide implications in apoptosis, proliferation, differ-
entiation and inflammation, among other functions [43,45–47]. The enzymes ultimately
responsible for SM synthesis, SM synthase (SMS) 1 and 2, transfer a phosphocholine moiety
from PC to ceramide, forming SM and diglycerides. Defects in SM synthesis may therefore
not only have direct but also indirect consequences, bringing together SM deficiencies with
PC, ceramide and DG metabolism, lipids with long recognized key specific structural and
signaling roles. The deficiency of SMS activity was reported to enhance cell migration in
an SMS1-SMS2 double-knockout cellular model [45]. However, we did not find significant
differences in SM levels between primary and metastatic phenotypes, whereby under-
representation of both SM species and SM class in melanoma is strongly associated with
malignancy but not with metastasis, at least in the collection of melanoma cell lines studied
here. It is of interest to bear in mind that, although altered SM levels have been reported in
numerous cancers, the specific changes seem to depend on the type of cancer. For instance,
increased SM levels were found in human hepatocellular carcinoma [48] but conversely,
and in line with the lipid changes reported here, SM levels dropped in colorectal [49] and
breast cancer [50] cell lines as well as in prostate cancer tissue [51] and clear cell renal
cell carcinoma [16] relative to non-malignant tissues. The fact that SM synthesis is finely
regulated not only at the SMS step but also at multiple levels involving the metabolism of
other lipids and numerous protein-mediated inter-organelles transport systems [43] may
underlie the different responses to particular oncogenic stimuli.
Kim et al. [29] identified five PI species and one PG that differentiated melanomas with
low and high metastatic potential, as well as malignant melanoma and normal melanocytes.
Here, we found that two PI species containing polyunsaturated fatty acids (40:4 and 40:6)
and three PG harboring low unsaturated acyl chains also discriminate melanoma from
normal melanocytes and seven more PI species distinguish MM from NM. In addition, we
found increased PI class levels in MM relative to PM cells. Except for one PI, the identities
of the species were not the same, possibly due to the differences in the experimental
approach, both in terms of the number of cell lines analyzed and the analytical procedures
used. In the present study, we employed UHPLC-MSE-based untargeted lipidomics, which
greatly enhances sensitivity for low abundance lipids and the accuracy of identification. By
contrast, Kim et al. used a DIMS-based lipidomics assay [29], which is known to be prone
to ion suppression due to the absence of a previous separation step, also compromising
identification. Previous comparative studies on the ability of DIMS and HPLC-MS to
identify renal cancer biomarkers also concluded that the latter was able to identify a larger
number of biomarkers and found differences in the identities [52]. Moreover, as intratumor
heterogeneity is inherent to tumor development, we examined a robust number of cell
lines to explore what could be considered a “consensus panel of lipid components,” i.e.,
lipids consistently expressed in melanocytic cells. Although it may appear that there
are discrepancies between these two studies, one similar message emerges: metastatic
melanoma herein and highly metastatic melanoma in Kim et al.’s [29] study are enriched
in PI lipids. Although PI accounts for only a small fraction of the plasma membrane lipids,
it plays a critical role in the cell, especially in signal transduction [27].
From a biological standpoint, a general consideration to have in mind is that changes
in lipid species may be viewed as either metabolic compensation, with or without appar-
ent impact on cell function, or in terms of the provision or decline of a particular lipid
responsible for or involved in a given biological process. As shown in Figure 1, a huge
interconnection of the glycerophospholipid biosynthetic pathways takes place in the ER,
with the exception of some reactions that occur in peroxisomes and mitochondria and that
are involved in the synthesis of ether lipids and phosphatidylglycerol-containing lipids,
respectively. Moreover, while the role of most lipid classes is well established, limited infor-
mation is available on the role of individual species other than the influence of the length
and saturation of acyl chain composition on the biophysical properties of membranes and
the response to proinflammatory signals. Fortunately, this information is being expanded
by the application of MS to the analysis of lipids [27]
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Finally, some caution should be exerted when drawing inferences from this study
as cell lines do not model all facets of melanocytes/melanoma in situ. One of the most
apparent limitations is that the FA profile of cells in culture often differs markedly from that
of cells in a tissue [53], where cells are exposed to a changing variety of nutrients in their
environment, oxygen availability fluctuates and extracellular matrix interactions occur.
Furthermore, melanoma shows impressive metabolic plasticity and might switch between
coexisting phenotypes during tumorigenesis. Here, we reveal lipid species and surrogate
metabolic processes that differ substantially between cells cultured in vitro, paving the
way to identify potential biomarkers and therapeutic opportunities that target metabolic
networks in melanoma. However, validation of these data in vivo will be essential using
IMS of lipids or other spatial phenotypic techniques on biopsies or true samples of patient-
derived melanomas and nevi melanocytes.
In conclusion, through a lipidomics analysis, we reveal alterations to the lipid profiles
of melanocytes that appear to be related to their benign and malignant transformation. We
found 32 putative melanoma lipid biomarkers; one of them had already been identified
previously [29], six lipid species were related to metastasis and 10 discriminate nevus
melanocytes from epidermal melanocytes. Unraveling the lipidomic profile of nevus
melanocytes and comparing it to that of primary melanoma cells is of utmost interest to
decipher the lipid contribution in the realm of benign/malignant transformation.
4. Materials and Methods
4.1. Subjects, Cell Culture and Sample Preparation for Lipidomic Analysis
Primary melanoma (PM: SK-MEL-28, SK-MEL-31, G-361, MEL-HO and A375), metastatic
melanoma (MM: RPMI-7951, Hs294T, A2058, SK-MEL-3 and Colo-800) and human epi-
dermal melanocyte (HeM: HEMn-LP, HEMn-MP, and HEMn-DP) cell lines were obtained
from the American Type Culture Collection (ATCC, Manassas, VA, USA), Thermo Fisher
Scientific (Waltham, MA, USA) or Innoprot SL (Derio, Spain). Melanocytes from his-
tologically confirmed, benign melanocytic nevi lesions (n = 8) were isolated [54] and
characterized according to our previously reported procedure [55]. Nevi were collected by
the Basque Biobank for Research-OEHUN (http://www.biobancovasco.org, accessed on
24 October 2021), having previously obtained signed informed consent from donors. All
the experiments carried out in this study were approved by the Euskadi Ethics Committee
(Oncoimage, 14/10).
Melanoma cells were propagated in EMEM (ATCC), DMEM (Sigma-Aldrich, Burling-
ton, MA, USA) or McCoy’s 5A medium (Life Technologies, Carlsbad, CA, USA) supple-
mented with 2 mM L-glutamine (Sigma-Aldrich), or in RPMI 1640-Glutamax™ (Life Tech-
nologies). The different culture media were supplemented with 10% FBS (GE Healthcare,
Chicago, IL, USA), 100 U/ml penicillin and 100 mg/ml streptomycin (Life Technologies),
according to the manufacturer’s instructions. Primary human melanocytes were cultured
in Medium 254 supplemented with 1X human melanocyte growth supplement (Life Tech-
nologies) in the absence of antibiotics. Cells were cultured at 37 ◦C with 5% CO2 and
95% humidity.
Lipid extraction was performed as described previously [56]. Briefly, cell pellets
were first rinsed twice and homogenized in 0.5–1 mL PBS using a Polytron homogenizer
(Kinematica AG, Malters, Switzerland), and the protein concentration of the homogenate
was determined (Bio-Rad protein assay kit, Thermo Fisher Scientific). Lipids were extracted
twice from homogenates (1 mg protein) with chloroform and methanol and the lower lipid-
rich chloroform phases were combined in a new tube and solvents evaporated under
vacuum (Savant SpeedVac concentrator, Thermo Fisher Scientific). The dried extracts were
reconstituted in chloroform:methanol (2:1, v/v), transferred to liquid chromatography vials
and the solvents dried. Finally, the extracts were stored at −80 ◦C under an N2 atmosphere
prior to their injection into the UHPLC-MSE system. Equal aliquots of each sample were
pooled to make quality control samples for periodic analysis of repeatability.
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4.2. UHPLC-MSE Analysis
Global lipidomic profiles were determined by tandem MS using an ESI in the negative
(−) and positive (+) ion mode after the separation of lipid classes by a reverse-phase UHPLC
technique. The chromatographic separation was achieved on an ACQUITY UPLCTM
system from Waters (Milford, MA, USA), equipped with a binary solvent delivery pump,
an autosampler and a column oven. A reverse-phase column (Acquity UHPLC HSS T3,
100 × 2.1 mm, 1.8 µm) and a pre-column (Acquity UHPLC HSS T3 1.8 µm VanGuard™),
both from Waters, were used. The mobile phases and UHPLC settings are shown in Table
S2, and the analysis was based on our previous report [57].
All UHPLC-MSE data were acquired on a SYNAPT G2 HDMS, with a quadrupole time
of flight (Q-ToF) configuration (Waters) equipped with an ESI source operating in positive
and negative ion modes. The optimized settings are detailed in Table S2. The spectra were
acquired over the 50–1200 m/z range and automatically corrected during acquisition using
the lock mass with leucine encephalin solution (2 ng/µL) in acetonitrile:water (50:50, v/v)
and 0.1% formic acid. The reference internal standards were introduced into the lock mass
sprayer at a constant flow rate of 10 µL/min using an external pump.
The UHPLC-MSE data generated were extracted with MSE Data Viewer [58]. This
software generates an exportable text file, which was used for lipid identification using
SimLipid [59]. The identity of the compounds was elucidated using the low-collision
energy MSE spectrum in positive and negative modes to determine the MW, and the high-
collision energy MSE spectrum to elucidate other structural details. The mass tolerance
window was set to 5 ppm for precursor and product ions. Annotation was reinforced by
comparing theoretical to experimental MS/MS spectra (Figure S4) and assessment of the
intensity of the carboxylate ion peaks corresponding to the fatty acyl chains on the sn-1
and sn-2 positions of the glycerol backbone (Figure S5).
The nomenclature and shorthand notation of lipid species was reported as recom-
mended in the LIPIDMAPS update report [60]. Whenever possible, annotation is given
at the sn-position (i.e.: PC 16:0/18:1), but FA positions may be unknown (PC 16:0_18:1)
or unidentified (PC 34:1). The UHPLC-MSE platform differentiated the ether and vinyl
ether bonds of alkyls at the sn-1 position of the glycerol backbone from the diacyl GPL
(represented by O- and P-, respectively).
4.3. Data Processing and Statistical Analysis
Raw MS data, acquired with MassLynx 4.1 [61], were converted into NetCDF files [62]
and processed [63]) to generate a table of time-aligned features, with the retention time
(RT), m/z and intensity values for each sample. The Matched Filter detection algorithm
was used for peak identification and the R-package CAMERA 1.22.0 [64] to exclude the
detected isotopologues of molecular entities. The peak marker tables (comprising m/z-
RT pairs and their corresponding intensities) were exported to SIMCA 15.0.2 [65] for
multivariate statistical analysis and to SPSS 26 [66] and Mass Profiler Professional B14.8 [67]
for univariate analysis.
Differences in the lipid fingerprints among the groups were examined using multivari-
ate statistical methods, including a principal components analysis (PCA) and partial least
square and orthogonal partial least square-discriminant analysis (PLSA-DA and OPLS-DA,
respectively). The data matrix of the original features was logarithmically transformed
[log10(xij + 1)] to improve the normality and homoscedasticity, and centered using Mean
Centering in the SIMCA software prior to performing the multivariate data analysis. We
explored unsupervised PCA as an overview to look for trends and groupings and super-
vised PLS-DA to generate predictive models that were validated by means of permutation
test and their p-values obtained from CV-ANOVA (Analysis of Variance testing of Cross-
Validated predictive residuals). To select discriminant lipids, we explored the OPLS-DA
models and further confirmed these using ANOVA and post-hoc testing with HSD-Tukey
or Games–Howell after performing Levene’s test to assess the equivalence of variances of
the groups (Games–Howell if p ≤ 0.05; HSD-Tukey if p ≥ 0.05).
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We also carried out univariate studies using ANOVA analysis corrected with a post-
hoc HSD Tukey or Games–Howell approach (see above) and applying a p ≤ 0.05 to
determine the significant inter-group differences. Volcano plots and heatmaps were also
obtained to identify inter-group differences in lipid composition, with a fold change >2
and p ≤ 0.05 by Student’s t-test using Benjamini–Hochberg FDR < 5% as a multiple
testing correction.
5. Patents
European patent No. EP21382988.0, “Method for the diagnosis of melanoma”, IMG
Pharma Biotech, S.L. and Universidad del País Vasco/Euskal Herriko Unibertsitatea. Ap-
plication date: 3 November 2021.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/ijms222112061/s1: Table S1: list of lipid species identified by lipidomics in melanocytic cells;
along with the relative intensity in each independent sample and the corresponding peak markers
(mass to charge ratio (m/z) and retention time (RT) pairs); Table S2: ultra-high-performance liquid
chromatography (UHPLC) and mass spectrometry (MS) settings; Figure S1: screening for lipid species
with a significant change in relative abundance using volcano plot analysis and heatmap clustering;
Figure S2: relative abundance of four selected lipid species; Figure S3: the relative abundance of some
lipid classes differs significantly among the cell groups; Figure S4: lipid identification workflow;
Figure S5: MS/MS spectra of the precursor ions of representative species of PC; PE; PI; PS and PG.
Author Contributions: Conceptualization; M.D.B.; B.O.; E.A.; G.B.-G. and J.A.F.; methodology; B.O.;
M.D.B. and B.A.-G.; software; B.A.-G.; investigation; A.P.-V. and B.A.-G.; resources; G.B.-G.; M.D.B.;
B.O.; A.A. and P.A.; data curation; B.A-G.; writing—original draft preparation; A.P-V.; O.F. and B.O.;
writing—review and editing; M.D.B.; B.O.; E.A.; G.B.-G.; A.A.; P.A. and J.A.F.; visualization; O.F.;
B.A.-G. and B.O.; supervision; M.D.B. and B.O.; project administration; M.D.B.; B.O.; J.A.F. and E.A.;
funding acquisition; M.D.B.; E.A.; J.A.F.; B.O.; G.B.-G. and A.A. All authors have read and agreed to
the published version of the manuscript.
Funding: This research was funded in part by grants from the Ministry of Economy; Industry
and Competitiveness (RTC-2015-3693-1); Ministry of Science and Innovation (RTI-2018-095134-B-
I00); Basque Government (IT971-16; IT1162-19; KK2016-036; KK2017-041 and KK2018-00090) and
UPV/EHU (GIU17/066).
Institutional Review Board Statement: The study was conducted according to the guidelines of the
Declaration of Helsinki; and the Euskadi Ethics Committee (Oncoimage; 14/10) approved all the
experiments carried out in this study.
Informed Consent Statement: Signed informed consent was obtained from all subjects involved in
the study.
Data Availability Statement: The data that support the findings of this study are available from the
corresponding author upon reasonable request.
Acknowledgments: A.P-V. was a doctoral student supported by the University of the Basque Country.
We are grateful to the Basque Biobank for the collection of tissue samples; to Cristina Penas for
her technical support in melanocytes isolations from biopsies and to SGiker Lipidomic Service
(UPV/EHU; MICINN; GV/EG; ESF) for the expert advice and technical and human support in
UHPLC-MSE analysis.
Conflicts of Interest: The authors have no conflict of interest to declare.
References
1. Kaufman, C.K.; Mosimann, C.; Fan, Z.P.; Yang, S.; Thomas, A.; Ablain, J.; Tan, J.L.; Fogley, R.D.; van Rooijen, E.; Hagedorn, E.; et al.
A Zebrafish Melanoma Model Reveals Emergence of Neural Crest Identity during Melanoma Initiation. Science 2016, 351, aad2197.
[CrossRef]
2. Gogas, H.; Eggermont, A.M.M.; Hauschild, A.; Hersey, P.; Mohr, P.; Schadendorf, D.; Spatz, A.; Dummer, R. Biomarkers in
Melanoma. Ann. Oncol. 2009, 20, vi8–vi13. [CrossRef] [PubMed]
3. Pavlova, N.N.; Thompson, C.B. The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016, 23, 27–47. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 12061 18 of 20
4. Nájera, L.; Alonso-Juarranz, M.; Garrido, M.; Ballestín, C.; Moya, L.; Martínez-Díaz, M.; Carrillo, R.; Juarranz, A.; Rojo, F.;
Cuezva, J.M.; et al. Prognostic Metabolic Markers in Cutaneous Melanoma. Br. J. Dermatol. 2019, 181, e10. [CrossRef]
5. Neagu, M. Metabolic Traits in Cutaneous Melanoma. Front. Oncol. 2020, 10, 851. [CrossRef]
6. Avagliano, A.; Fiume, G.; Pelagalli, A.; Sanità, G.; Ruocco, M.R.; Montagnani, S.; Arcucci, A. Metabolic Plasticity of Melanoma
Cells and Their Crosstalk with Tumor Microenvironment. Front. Oncol. 2020, 10, 722. [CrossRef] [PubMed]
7. Hanahan, D.; Weinberg, R.A. Hallmarks of Cancer: The Next Generation. Cell 2011, 144, 646–674. [CrossRef]
8. DeBerardinis, R.J.; Lum, J.J.; Hatzivassiliou, G.; Thompson, C.B. The Biology of Cancer: Metabolic Reprogramming Fuels Cell
Growth and Proliferation. Cell Metab. 2008, 7, 11–20. [CrossRef] [PubMed]
9. DeBerardinis, R.J.; Sayed, N.; Ditsworth, D.; Thompson, C.B. Brick by Brick: Metabolism and Tumor Cell Growth. Curr. Opin.
Genet. Dev. 2008, 18, 54–61. [CrossRef] [PubMed]
10. DeBerardinis, R.J.; Chandel, N.S. Fundamentals of Cancer Metabolism. Sci. Adv. 2016, 2, e1600200. [CrossRef] [PubMed]
11. Hilvo, M.; Denkert, C.; Lehtinen, L.; Müller, B.; Brockmöller, S.; Seppänen-Laakso, T.; Budczies, J.; Bucher, E.; Yetukuri, L.;
Castillo, S.; et al. Novel Theranostic Opportunities Offered by Characterization of Altered Membrane Lipid Metabolism in Breast
Cancer Progression. Cancer Res. 2011, 71, 3236–3245. [CrossRef] [PubMed]
12. Menendez, J.A.; Lupu, R. Fatty Acid Synthase and the Lipogenic Phenotype in Cancer Pathogenesis. Nat. Rev. Cancer 2007, 7,
763–777. [CrossRef] [PubMed]
13. Li, J.; Cheng, J.-X. Direct Visualization of De Novo Lipogenesis in Single Living Cells. Sci. Rep. 2014, 4, 6807. [CrossRef]
14. Nomura, D.K.; Long, J.Z.; Niessen, S.; Hoover, H.S.; Ng, S.-W.; Cravatt, B.F. Monoacylglycerol Lipase Regulates a Fatty Acid
Network That Promotes Cancer Pathogenesis. Cell 2010, 140, 49–61. [CrossRef]
15. Baba, Y.; Funakoshi, T.; Mori, M.; Emoto, K.; Masugi, Y.; Ekmekcioglu, S.; Amagai, M.; Tanese, K. Expression of Monoacylglycerol
Lipase as a Marker of Tumour Invasion and Progression in Malignant Melanoma. J. Eur. Acad. Dermatol. Venereol. 2017, 31,
2038–2045. [CrossRef]
16. Saito, K.; Arai, E.; Maekawa, K.; Ishikawa, M.; Fujimoto, H.; Taguchi, R.; Matsumoto, K.; Kanai, Y.; Saito, Y. Lipidomic Signatures
and Associated Transcriptomic Profiles of Clear Cell Renal Cell Carcinoma. Sci. Rep. 2016, 6, 28932. [CrossRef]
17. Currie, E.; Schulze, A.; Zechner, R.; Walther, T.C.; Farese, R.V. Cellular Fatty Acid Metabolism and Cancer. Cell Metab. 2013, 18,
153–161. [CrossRef]
18. Röhrig, F.; Schulze, A. The Multifaceted Roles of Fatty Acid Synthesis in Cancer. Nat. Rev. Cancer 2016, 16, 732–749. [CrossRef]
19. Vogel, F.C.E.; Bordag, N.; Zügner, E.; Trajkovic-Arsic, M.; Chauvistré, H.; Shannan, B.; Váraljai, R.; Horn, S.; Magnes, C.; Thomas
Siveke, J.; et al. Targeting the H3K4 Demethylase KDM5B Reprograms the Metabolome and Phenotype of Melanoma Cells. J.
Investig. Dermatol. 2019, 139, 2506–2516.e10. [CrossRef]
20. Vazquez, F.; Lim, J.-H.; Chim, H.; Bhalla, K.; Girnun, G.; Pierce, K.; Clish, C.B.; Granter, S.R.; Widlund, H.R.; Spiegelman, B.M.; et al.
PGC1α Expression Defines a Subset of Human Melanoma Tumors with Increased Mitochondrial Capacity and Resistance to
Oxidative Stress. Cancer Cell 2013, 23, 287–301. [CrossRef] [PubMed]
21. Jeon, T.-I.; Osborne, T.F. SREBPs: Metabolic Integrators in Physiology and Metabolism. Trends Endocrinol. Metab. 2012, 23, 65–72.
[CrossRef]
22. Shao, W.; Espenshade, P.J. Expanding Roles for SREBP in Metabolism. Cell Metab. 2012, 16, 414–419. [CrossRef]
23. Talebi, A.; Dehairs, J.; Rambow, F.; Rogiers, A.; Nittner, D.; Derua, R.; Vanderhoydonc, F.; Duarte, J.A.G.; Bosisio, F.;
Van den Eynde, K.; et al. Sustained SREBP-1-Dependent Lipogenesis as a Key Mediator of Resistance to BRAF-Targeted Therapy.
Nat. Commun. 2018, 9, 2500. [CrossRef]
24. Pascual, G.; Avgustinova, A.; Mejetta, S.; Martín, M.; Castellanos, A.; Attolini, C.S.-O.; Berenguer, A.; Prats, N.; Toll, A.;
Hueto, J.A.; et al. Targeting Metastasis-Initiating Cells through the Fatty Acid Receptor CD36. Nature 2017, 541, 41–45. [CrossRef]
[PubMed]
25. Zhang, M.; Di Martino, J.S.; Bowman, R.L.; Campbell, N.R.; Baksh, S.C.; Simon-Vermot, T.; Kim, I.S.; Haldeman, P.; Mondal, C.;
Yong-Gonzales, V.; et al. Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins. Cancer Discov. 2018, 8,
1006–1025. [CrossRef] [PubMed]
26. Rodriguez-Gallardo, S.; Kurokawa, K.; Sabido-Bozo, S.; Cortes-Gomez, A.; Ikeda, A.; Zoni, V.; Aguilera-Romero, A.; Perez-Linero,
A.M.; Lopez, S.; Waga, M.; et al. Ceramide Chain Length–Dependent Protein Sorting into Selective Endoplasmic Reticulum Exit
Sites. Sci. Adv. 2020, 6, eaba8237. [CrossRef]
27. Kimura, T.; Jennings, W.; Epand, R.M. Roles of Specific Lipid Species in the Cell and Their Molecular Mechanism. Prog. Lipid Res.
2016, 62, 75–92. [CrossRef] [PubMed]
28. Han, X.; Gross, R.W. Global Analyses of Cellular Lipidomes Directly from Crude Extracts of Biological Samples by ESI Mass
Spectrometry: A Bridge to Lipidomics. J. Lipid Res. 2003, 44, 1071–1079. [CrossRef]
29. Kim, H.-Y.; Lee, H.; Kim, S.-H.; Jin, H.; Bae, J.; Choi, H.-K. Discovery of Potential Biomarkers in Human Melanoma Cells with
Different Metastatic Potential by Metabolic and Lipidomic Profiling. Sci. Rep. 2017, 7, 8864. [CrossRef]
30. Schroeder, F.; Gardiner, J.M. Membrane Lipids and Enzymes of Cultured High- and Low-Metastatic B16 Melanoma Variants.
Cancer Res. 1984, 44, 9.
31. Garate, J.; Lage, S.; Fernández, R.; Velasco, V.; Abad, B.; Asumendi, A.; Gardeazabal, J.; Arroyo-Berdugo, Y.; Rodríguez, M.Á.;
Artola, J.L.; et al. Imaging Mass Spectrometry–Based Lipidomic Approach to Classification of Architectural Features in Nevi.
J. Investig. Dermatol. 2019, 139, 2055–2058. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2021, 22, 12061 19 of 20
32. Kim, J.; Hoppel, C.L. Identification of Unusual Phospholipids from Bovine Heart Mitochondria by HPLC-MS/MS. J. Lipid Res.
2020, 61, 1707–1719. [CrossRef]
33. Bestard-Escalas, J.; Maimó-Barceló, A.; Lopez, D.H.; Reigada, R.; Guardiola-Serrano, F.; Ramos-Vivas, J.; Hornemann, T.;
Okazaki, T.; Barceló-Coblijn, G. Common and Differential Traits of the Membrane Lipidome of Colon Cancer Cell Lines and Their
Secreted Vesicles: Impact on Studies Using Cell Lines. Cancers 2020, 12, 1293. [CrossRef]
34. van Meer, G.; Voelker, D.R.; Feigenson, G.W. Membrane Lipids: Where They Are and How They Behave. Nat. Rev. Mol. Cell Biol.
2008, 9, 112–124. [CrossRef] [PubMed]
35. Dorninger, F.; Forss-Petter, S.; Berger, J. From Peroxisomal Disorders to Common Neurodegenerative Diseases—The Role of Ether
Phospholipids in the Nervous System. FEBS Lett. 2017, 591, 2761–2788. [CrossRef]
36. Braverman, N.E.; Moser, A.B. Functions of Plasmalogen Lipids in Health and Disease. Biochim. Biophys. Acta Mol. Basis Dis. 2012,
1822, 1442–1452. [CrossRef] [PubMed]
37. Jiménez-Rojo, N.; Leonetti, M.D.; Zoni, V.; Colom, A.; Feng, S.; Iyengar, N.R.; Matile, S.; Roux, A.; Vanni, S.; Weissman, J.S.; et al.
Conserved Functions of Ether Lipids and Sphingolipids in the Early Secretory Pathway. Curr. Biol. 2020, 30, 3775–3787. [CrossRef]
38. Wallner, S.; Schmitz, G. Plasmalogens the Neglected Regulatory and Scavenging Lipid Species. Chem. Phys. Lipids 2011, 164,
573–589. [CrossRef]
39. Jiménez-Rojo, N.; Riezman, H. On the Road to Unraveling the Molecular Functions of Ether Lipids. FEBS Lett. 2019, 593,
2378–2389. [CrossRef] [PubMed]
40. Paul, S.; Lancaster, G.I.; Meikle, P.J. Plasmalogens: A Potential Therapeutic Target for Neurodegenerative and Cardiometabolic
Disease. Prog. Lipid Res. 2019, 74, 186–195. [CrossRef]
41. Cui, W.; Liu, D.; Gu, W.; Chu, B. Peroxisome-Driven Ether-Linked Phospholipids Biosynthesis Is Essential for Ferroptosis. Cell
Death Differ. 2021, 28, 2536–2551. [CrossRef] [PubMed]
42. Gallego-García, A.; Monera-Girona, A.J.; Pajares-Martínez, E.; Bastida-Martínez, E.; Pérez-Castaño, R.; Iniesta, A.A.; Fontes, M.;
Padmanabhan, S.; Elías-Arnanz, M. A Bacterial Light Response Reveals an Orphan Desaturase for Human Plasmalogen Synthesis.
Science 2019, 366, 128–132. [CrossRef] [PubMed]
43. D’Angelo, G.; Moorthi, S.; Luberto, C. Role and Function of Sphingomyelin Biosynthesis in the Development of Cancer. In
Advances in Cancer Research; Elsevier: Amsterdam, The Netherlands, 2018; Volume 140, pp. 61–96. ISBN 978-0-12-814223-3.
44. Ogretmen, B. Sphingolipid Metabolism in Cancer Signalling and Therapy. Nat. Rev. Cancer 2018, 18, 33–50. [CrossRef] [PubMed]
45. Asano, S.; Kitatani, K.; Taniguchi, M.; Hashimoto, M.; Zama, K.; Mitsutake, S.; Igarashi, Y.; Takeya, H.; Kigawa, J.;
Hayashi, A.; et al. Regulation of Cell Migration by Sphingomyelin Synthases: Sphingomyelin in Lipid Rafts Decreases
Responsiveness to Signaling by the CXCL12/CXCR4 Pathway. Mol. Cell. Biol. 2012, 32, 3242–3252. [CrossRef]
46. Bartke, N.; Hannun, Y.A. Bioactive Sphingolipids: Metabolism and Function. J. Lipid Res. 2009, 50, S91–S96. [CrossRef]
47. Codini, M.; Garcia-Gil, M.; Albi, E. Cholesterol and Sphingolipid Enriched Lipid Rafts as Therapeutic Targets in Cancer. Int. J.
Mol. Sci. 2021, 22, 726. [CrossRef]
48. Li, Z.; Guan, M.; Lin, Y.; Cui, X.; Zhang, Y.; Zhao, Z.; Zhu, J. Aberrant Lipid Metabolism in Hepatocellular Carcinoma Revealed
by Liver Lipidomics. Int. J. Mol. Sci. 2017, 18, 2550. [CrossRef]
49. Lemonnier, L.A.; Dillehay, D.L.; Vespremi, M.J.; Abrams, J.; Brody, E.; Schmelz, E.M. Sphingomyelin in the Suppression of Colon
Tumors: Prevention versus Intervention. Arch. Biochem. Biophys. 2003, 419, 129–138. [CrossRef]
50. Wang, S.; Chen, X.; Luan, H.; Gao, D.; Lin, S.; Cai, Z.; Liu, J.; Liu, H.; Jiang, Y. Matrix-Assisted Laser Desorption/Ionization
Mass Spectrometry Imaging of Cell Cultures for the Lipidomic Analysis of Potential Lipid Markers in Human Breast Cancer
Invasion: Mass Spectrometry Imaging of Lipids in Human Breast Cancer Invasion. Rapid Commun. Mass Spectrom. 2016, 30,
533–542. [CrossRef]
51. Narayan, P.; Dahiya, R. Alterations in Sphingomyelin and Fatty Acids in Human Benign Prostatic Hyperplasia and Prostatic
Cancer. Biomed. Biochim. Acta 1991, 50, 1099–1108.
52. Lin, L.; Yu, Q.; Yan, X.; Hang, W.; Zheng, J.; Xing, J.; Huang, B. Direct Infusion Mass Spectrometry or Liquid Chromatography Mass
Spectrometry for Human Metabonomics? A Serum Metabonomic Study of Kidney Cancer. Analyst 2010, 135, 2970. [CrossRef]
[PubMed]
53. Else, P.L. The Highly Unnatural Fatty Acid Profile of Cells in Culture. Prog. Lipid Res. 2020, 77, 101017. [CrossRef] [PubMed]
54. Herlyn, M.; Rodeck, U.; Jambrosic, J.; Koprowski, H. Expression of Melanoma-Associated Antigens in Rapidly Dividing Human
Melanocytes in Culture. Cancer Res. 1987, 15, 3057–3061.
55. García-Vázquez, M.D.; Boyano, M.D.; Cañavate, M.L.; Gardeazabal, J.; de Galdeano, A.G.; López-Michelena, T.; Ratón, J.A.;
Izu, R.; Díaz-Ramón, J.L.; Díaz-Pérez, J.L. Interleukin-2 Enhances the Growth of Human Melanoma Cells Derived Form Primary
but Not from Metastatic Tumours. Eur. Cytokine Netw. 2000, 11, 654–661. [PubMed]
56. Fernández, R.; Garate, J.; Abad, B.; Ochoa, B.; Fernández, J.A. Mapping lipid distribution in rat sciatic nerve using imaging mass
spectrometry. In Myelin; Woodhoo, A., Ed.; Methods in Molecular Biology; Springer: New York, NY, USA, 2018; Volume 1791, pp.
51–65, ISBN 978-1-4939-7861-8.
57. Iriondo, A.; Tainta, M.; Saldias, J.; Arriba, M.; Ochoa, B.; Goñi, F.M.; Martinez-Lage, P.; Abad-García, B. Isopropanol Extraction for
Cerebrospinal Fluid Lipidomic Profiling Analysis. Talanta 2019, 195, 619–627. [CrossRef]
58. MSE Data Viewer; Waters MS Technologies: Manchester, UK, 2012.
59. SimLipid; Version 6.04; Premier Biosoft: Palo Alto, CA, USA, 2018.
Int. J. Mol. Sci. 2021, 22, 12061 20 of 20
60. Liebisch, G.; Fahy, E.; Aoki, J.; Dennis, E.A.; Durand, T.; Ejsing, C.S.; Fedorova, M.; Feussner, I.; Griffiths, W.J.; Köfeler, H.; et al.
Update on LIPID MAPS Classification, Nomenclature, and Shorthand Notation for MS-Derived Lipid Structures. J. Lipid Res.
2020, 61, 1539–1555. [CrossRef]
61. MassLynx Mass Spectrometry Software, version 4.1; Waters: Milford, MA, USA, 2012.
62. DataBridge Converter, version 3.5; Waters: Milford, MA, USA, 2012.
63. XCMS, version 1.42.0; METLIN: La Jolla, CA, USA, 2015.
64. R-Package CAMERA, version 1.22.0; Bioconductor: Seattle, WA, USA, 2015.
65. SIMCA, version 15.0.2; Umetrics: Umea, Sweden, 2018.
66. SPSS, version 26; IBM: Armonk, NY, USA, 2019.
67. Mass Profiler Professional, version B14.8; Agilent Technologies: Barcelona, Spain, 2016.
